Bone and Joint Infection
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
MaaT PharmaFrance - Lyon
1 programBiological samples collection of blood and fecesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsTedizolid
MaaT PharmaBiological samples collection of blood and feces
Clinical Trials (2)
Total enrollment: 106 patients across 2 trials
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Start: Feb 2017Est. completion: Aug 202144 patients
Phase 2Completed
InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS
Start: Dec 2016Est. completion: Mar 201862 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.